文献速递细菌感染、耐药与抗菌药物医院感染防控

重症成人呼吸机相关性肺炎患者口服米诺环素的人群药代动力学模型

Population pharmacokinetic model of oral minocycline in critically ill adult patients with ventilator-associated pneumonia.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

一项前瞻性、开放标签研究纳入24例多重耐药鲍曼不动杆菌呼吸机相关性肺炎重症成人患者,建立口服米诺环素的人群药代动力学模型,采用一室模型加一级吸收和线性消除描述数据,并通过蒙特卡洛模拟评估不同MIC下的PTA。

要点

  • 口服米诺环素表观分布容积183.3 L、表观清除率6.55 L/h、吸收速率常数1.66 h⁻¹。
  • 日剂量400 mg时,仅MIC≤0.25 mg/L可达fAUC/MIC>25的充分暴露。
  • fAUC/MIC=13.75时,至MIC=0.5 mg/L仍计算得高PTA值。

核心结论

  • 本研究为重症成人患者口服米诺环素提供了人群药代动力学模型,有助于更好地理解米诺环素的药代动力学,并可为给药策略及未来重症监护环境中米诺环素使用的研究提供信息。

研究设计与样本

  • 前瞻性、开放标签研究,纳入24例多重耐药鲍曼不动杆菌呼吸机相关性肺炎重症患者。
  • 建立口服米诺环素的人群药代动力学模型,并通过蒙特卡洛模拟评估不同MIC下的PTA。
  • 一室模型加一级吸收和线性消除最佳描述数据。

主要发现

  • 估计的人群参数:表观分布容积(V/F)为183.3 L,表观清除率(CL/F)为6.55 L/h,吸收速率常数(ka)为1.66 h⁻¹(F代表口服生物利用度)。
  • PTA分析显示,日剂量400 mg时,仅MIC≤0.25 mg/L可达充分暴露(游离AUC/MIC即fAUC/MIC>25)。
  • 对于fAUC/MIC=13.75,至MIC=0.5 mg/L仍计算得高PTA值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Multidrug-resistant Acinetobacter baumannii (MDR-A. baumannii) has become an emerging pathogen, causing ventilator-associated pneumonia (VAP), with limited treatment options available. MIN has re-emerged as a potential treatment option for MDR pathogens. However, evidence regarding MIN pharmacokinetic properties in critically ill patients is scarce and primarily limited to IV administration. To address the knowledge gap in regions where IV MIN is unavailable, a prospective, open-label study was conducted to describe the pharmacokinetic properties of orally administered MIN. METHODS: The study included 24 critically ill patients with MDR-A. baumannii VAP. A population PK (popPK) model was developed and the PTA for different MICs was assessed by Monte Carlo simulations. A one-compartment model with first-order absorption and linear elimination best described the data. RESULTS: The values of the estimated population parameters were found equal to 183.3 L, 6.55 L/h and 1.66 h⁻¹, for the apparent volume of distribution (V/F), the apparent clearance (CL/F) and the absorption rate constant (ka), respectively (F representing oral bioavailability). PTA analysis showed that for a daily dose of 400 mg, adequate exposure [free AUC/MIC (fAUC/MIC > 25)] was achieved only for MICs ≤ 0.25 mg/L, while for the ratio of fAUC/MIC = 13.75, high PTA values are calculated up to MIC = 0.5 mg/L. CONCLUSIONS: This study provides a popPK model for oral MIN in critically ill adults. The developed popPK model contributes to a better understanding of MIN's PK and can inform dosing strategies and future studies on MIN use in critical care settings.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Athanassa Z, Papakyriakopoulou P, Marquez Megias S, et al. Population pharmacokinetic model of oral minocycline in critically ill adult patients with ventilator-associated pneumonia. J Antimicrob Chemother. 2025. PMID: 40132622. doi:10.1093/jac/dkaf090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。